Description
Continuous Glucose Monitoring (CGM) Devices Market Overview
The global Continuous Glucose Monitoring (CGM) Devices Market is projected to grow from USD 5.33 billion in 2025 to USD 9.93 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 7.22% during the forecast period.
The global market for Continuous Glucose Monitoring (CGM) devices is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide. According to recent statistics, the number of individuals living with diabetes is expected to reach 700 million by 2045, underscoring the urgent need for advanced diabetes management solutions. CGM devices offer a non-invasive and continuous monitoring option for people with diabetes, reducing the need for frequent fingerstick tests and providing valuable insights into blood sugar trends.
With technological advancements and innovations in sensor design, CGM devices have become more accurate, user-friendly, and accessible to a wider population. These devices are equipped with sensors that are inserted subcutaneously and continuously measure glucose levels in the interstitial fluid. The data collected by CGM devices can be transmitted wirelessly to a smartphone or a receiver, allowing users to track their glucose levels in real-time and receive alerts for high or low blood sugar levels.
Continuous Glucose Monitoring (CGM) Devices Market Dynamics
Drivers
Improved Accuracy: CGM devices provide continuous and real-time glucose readings, offering a more accurate picture of blood sugar levels compared to traditional fingerstick testing.
Convenience: With CGM devices, individuals no longer need to prick their fingers multiple times a day, leading to improved compliance with monitoring routines.
Early Detection: The continuous monitoring capabilities of CGM devices enable the early detection of hypo- and hyperglycemia, allowing for timely intervention and prevention of complications.
Restraints
Cost: One of the main restraints of CGM devices is their cost, which can be prohibitive for some individuals, especially those without insurance coverage.
Accuracy Issues: CGM devices may sometimes provide inaccurate readings, leading to incorrect treatment decisions and potential health risks.
Skin Irritation: Prolonged use of CGM sensors may cause skin irritation or allergic reactions in some individuals, limiting their usability.
Challenges
Regulatory Hurdles: The regulatory approval process for CGM devices can be lengthy and complex, delaying their market availability and adoption.
Interoperability: Ensuring seamless communication and data integration between CGM devices and insulin pumps or other diabetes management tools remains a challenge.
User Education: Proper training and education on the use of CGM devices are essential but may not always be readily available to all individuals with diabetes.
Opportunities
Technological Advancements: Continuous advancements in sensor technology and data analytics present opportunities for further improving the accuracy and usability of CGM devices.
Remote Monitoring: The ability to remotely monitor glucose levels through CGM devices opens up new possibilities for telemedicine and virtual care in diabetes management.
Personalized Medicine: CGM devices can provide personalized insights and recommendations based on individual glucose patterns, enabling tailored treatment plans.
List of Key Players
- Dexcom
- Abbott (FreeStyle Libre series, Libre Rio, Lingo)
- Medtronic
- Senseonics (Eversense)
- Ypsomed
- Roche (Accu-Chek CGM)
- Hoffmann‑La Roche
- Menarini Diagnostics
- Ascensia Diabetes Care
- LifeScan
- Nemaura Medical (SugarBEAT)
- Signos
- Medtrum
- Nipro
- i‑Sens
- Ultrahuman (M1 CGM)
- Tandem Diabetes Care (via platform integrations)
- Ongoing R&D: Qure.ai, Vuno, etc.
Recent Developments:
Dexcom – April 10, 2025
FDA cleared Dexcom G7 15 Day CGM, now longest-lasting (15.5 days) and most accurate CGM for adults with diabetes.
Senseonics – June 4, 2025
Announced Eversense 365 CGM platform at ADA 2025, showcasing its implantable, 365-day wear sensor performance.
Abbott & Dexcom – June 2025 (the wellness trend)
CGMs are gaining OTC access: Abbott’s Lingo and Dexcom’s Stelo are now available without prescriptions for wellness and sport-oriented users.
Sequel Med Tech & Senseonics – April 29, 2025
Launched the first automated insulin delivery pump integration combining Sequel’s pump tech with Senseonics CGM, marking expansion into AID systems
Continuous Glucose Monitoring (CGM) Devices Market Segmentation
By Component
- Sensors (wearable patch units)
- Transmitters
- Receivers & Display Devices
- Integrated CGM systems (iCGMs compatible with AID platforms)
By End User
- Hospitals & Clinics
- Homecare & Self-monitoring
- Fitness & Wellness Enthusiasts
By Application
- Type 1 Diabetes
- Type 2 Diabetes
- Non-diabetic health tracking (biohacking, sports performance)
By Distribution Channel
- Prescription retail pharmacies
- Over-the-counter/Direct-to-Consumer
- Online & Digital Health Platforms
Regional Market Insights: A Breakdown by Region
North America
North America holds a significant share of the CGM devices market, driven by the high prevalence of diabetes in the region. The increasing adoption of advanced healthcare technologies, growing awareness about the benefits of continuous glucose monitoring, and favorable reimbursement policies are some of the key factors contributing to the growth of the market in North America.
Europe
Europe is another prominent market for CGM devices, with a strong focus on research and development in the healthcare sector. The region has witnessed a surge in the demand for CGM devices due to the rising diabetic population and increasing healthcare expenditure. Additionally, the presence of major market players and technological advancements in the field has further propelled the growth of the market in Europe.
Asia Pacific
The Asia Pacific region is experiencing rapid growth in the CGM devices market, fueled by the increasing awareness about diabetes management and the growing adoption of innovative healthcare solutions. The rising healthcare infrastructure, government initiatives to combat diabetes, and the expanding diabetic population are key factors driving the market in Asia Pacific.
Latin America
Latin America is also emerging as a significant market for CGM devices, with a growing focus on improving diabetes care and management. The region is witnessing a rise in the adoption of CGM devices due to the increasing prevalence of diabetes and the rising healthcare expenditure. Government initiatives to promote diabetes awareness and advancements in healthcare technology are further boosting the market in Latin America.
Middle East and Africa
The Middle East and Africa region are projected to show substantial growth in the CGM devices market, driven by the rising diabetic population and the increasing focus on healthcare infrastructure development. The growing adoption of digital health solutions, improving access to healthcare facilities, and government initiatives to address diabetes are expected to fuel the market in the Middle East and Africa.
Target Audience
Medical device makers (CGMs, AID systems)
Endocrinologists, diabetologists & primary care physicians
Patients with diabetes & wellness-focused consumers
Hospitals, clinics & home care providers
Retailers & digital pharmacies
Telehealth platforms integrating CGM data
Insurers & PBMs
Regulatory bodies (FDA, EMA, etc.)
Academic & clinical research centers
CROs focused on diabetes tech
Sports & fitness organizations (monitoring metabolic health)
Digital health startups & AI analytics firms
Investors & venture capital in medtech
